STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACIU
  4. [Form 4] AC Immune SA Insider Trading Activity

AC Immune (ACIU) interim CEO Martin Zuegel granted RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

AC Immune SA interim CEO Martin Zuegel reported equity compensation awards. On June 11, 2026, he received a grant of 33,136 restricted share units under the company’s 2016 Stock Option and Incentive Plan. Following this award, he holds 71,408 common shares underlying outstanding restricted share units.

On the same date, he was also granted share options on 77,778 common shares at an exercise price of $2.6200 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036. All reported holdings are direct.

Positive

  • None.

Negative

  • None.
Insider Zuegel Martin
Role Interim CEO
Type Security Shares Price Value
Grant/Award Share Option (right to buy) 77,778 $0.00 --
Grant/Award Common Share 33,136 $0.00 --
Holdings After Transaction: Share Option (right to buy) — 77,778 shares (Direct, null); Common Share — 71,408 shares (Direct, null)
Footnotes (1)
  1. On June 11, 2026, the Reporting Person received a restricted share unit grant of 33,136 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP). Comprised of 71,408 common shares underlying outstanding restricted share units. On June 11, 2026, the Reporting Person received share options with respect to 77,778 shares under the SOIP. The share options will fully vest on June 10, 2027.
RSU grant 33,136 units Restricted share units granted on June 11, 2026
RSU-based shares held 71,408 shares Common shares underlying outstanding RSUs following grant
Option grant size 77,778 options Share options granted on June 11, 2026
Option exercise price $2.6200 per share Exercise price for 77,778 share options
Option vesting date June 10, 2027 Date options will fully vest
Option expiration June 10, 2036 Expiration date of granted share options
restricted share unit financial
"received a restricted share unit grant of 33,136 units under the AC Immune SA 2016 Stock Option and Incentive Plan"
A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.
2016 Stock Option and Incentive Plan financial
"grant of 33,136 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP)"
share options financial
"received share options with respect to 77,778 shares under the SOIP"
Share options are contracts that give someone the right, but not the obligation, to buy a company’s stock at a predetermined price for a limited time—think of them like a coupon to purchase shares later at a set price. They matter to investors because when exercised they increase the number of outstanding shares (dilution), can change management incentives and company value, and represent a potential future claim on profits or equity.
exercise price financial
"share options on 77,778 common shares at an exercise price of $2.6200 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The share options will fully vest on June 10, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Zuegel Martin
(Last)(First)(Middle)
EPFL INNOVATION PARK, BUILDING B
(Street)
LAUSANNE1015
(City)(State)(Zip)
SWITZERLAND
(Country)		2. Issuer Name and Ticker or Trading Symbol
AC Immune SA [ ACIU ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Interim CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Share06/11/2026A33,136A$0(1)71,408(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (right to buy)$2.6206/11/2026A77,77806/10/2027(3)06/10/2036Common Share77,778$077,778D
Explanation of Responses:
1. On June 11, 2026, the Reporting Person received a restricted share unit grant of 33,136 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP).
2. Comprised of 71,408 common shares underlying outstanding restricted share units.
3. On June 11, 2026, the Reporting Person received share options with respect to 77,778 shares under the SOIP. The share options will fully vest on June 10, 2027.
Matthias Maurer as Attorney-in-Fact for Martin Zuegel06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did AC Immune (ACIU) interim CEO Martin Zuegel report in this Form 4?

He reported receiving equity compensation awards, not open-market trades. The filing shows a grant of restricted share units and a grant of stock options under AC Immune’s 2016 Stock Option and Incentive Plan, both awarded on June 11, 2026 as part of his compensation.

How many restricted share units did AC Immune (ACIU) grant to Martin Zuegel?

He received 33,136 restricted share units on June 11, 2026. After this award, his reported position includes 71,408 common shares underlying outstanding restricted share units, reflecting his accumulated RSU-based equity exposure in AC Immune SA as interim CEO.

What stock options did AC Immune (ACIU) grant to Martin Zuegel and at what price?

He was granted options on 77,778 common shares at an exercise price of $2.6200 per share. These options were awarded under the 2016 Stock Option and Incentive Plan and give him the right to buy shares at that fixed price if exercised.

When do Martin Zuegel’s new AC Immune (ACIU) stock options vest and expire?

The options will fully vest on June 10, 2027 and expire on June 10, 2036. Vesting means he must remain eligible until June 2027 to exercise, while the 2036 expiration is the final date the options can be exercised.

Are Martin Zuegel’s AC Immune (ACIU) holdings in this Form 4 direct or indirect?

All reported holdings are direct. The Form 4 lists his ownership type as direct for both the restricted share units underlying 71,408 common shares and the 77,778 stock options, with no indication of trusts or other indirect holding entities.